Pilot Use of a Novel DNA Methytransferase-1 (DNMT1) Flow Cytometric Pharmacodynamic Assay to Evaluate Response to Low-Dose Azacitidine Therapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse after Allogeneic Hematopoietic Cell Transplantation